Zobrazeno 1 - 10
of 67
pro vyhledávání: '"ZH. I. Avdeeva"'
Autor:
A. A. Soldatov, A. K. Yakovlev, Zh. I. Avdeeva, D. V. Gorenkov, A. S. Korovkin, V. V. Kosenko
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 24, Iss 3, Pp 335-347 (2024)
INTRODUCTION. The stability assessment of biological medicinal products (BMPs) requires special approaches and regulatory requirements. Therefore, BMPs require relevant national guidelines, which are an important prerequisite for the assurance of the
Externí odkaz:
https://doaj.org/article/a7794b50a9b84a0e9ce7418b155c8c81
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 23, Iss 4, Pp 513-529 (2023)
Scientific relevance. In recent years, the development of various vaccines based on novel platforms has underscored the significance of updating regulatory requirements for vaccines. Consequently, clinical trials of viral vaccines need harmonised app
Externí odkaz:
https://doaj.org/article/b47d6c2fb9a34e50a5f079d98ec7cfc4
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 23, Iss 1, Pp 7-25 (2023)
Vaccines are subject to specific regulatory requirements for the evaluation of their quality, safety, and efficacy. In 2005, the World Health Organisation (WHO), as the main international organisation coordinating measures to combat infectious diseas
Externí odkaz:
https://doaj.org/article/a6ada49ddbeb4215b4a68527cc963ec7
Autor:
A. A. Soldatov, Zh. I. Avdeeva, D. V. Gorenkov, L. M. Khantimirova, S. G. Guseva, V. A. Merkulov
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 22, Iss 1, Pp 6-22 (2022)
There are a lot of diseases known today, which are caused by genetic abnormalities. Advances in genetics and biotechnology brought about gene editing technologies that can produce almost any gene, which ultimately led to the emergence of a new class
Externí odkaz:
https://doaj.org/article/be78145874ca45f58a9c957d5c4e9b61
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 21, Iss 2, Pp 97-107 (2021)
Continuous replacement therapy with clotting factor products can lead to serious complications in haemophilia A patients. One of potential reasons of such complications is an undesirable immune response to a blood clotting factor VIII (FVIII) product
Externí odkaz:
https://doaj.org/article/4199322630aa482794e8c5c50a39311e
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 21, Iss 1, Pp 39-49 (2021)
According to the World Federation of Hemophilia (WFH), there are currently about 400 thousand patients with hemophilia in the world. Severe clinical manifestations of the disease associated with a genetically determined deficiency of blood clotting f
Externí odkaz:
https://doaj.org/article/1f8ca495c0374294b6614e09689b210a
Autor:
N. А. Alpatova, Zh. I. Avdeeva, S. L. Lysikova, O. V. Golovinskaya, L. A. Gayderova, V. P. Bondarev
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 21, Iss 1, Pp 20-30 (2021)
One of the major public health challenges today is development of new vaccines and technologies to optimize the vaccination process. There is a growing scientific interest in vaccine adjuvants that enhance vaccine immunogenicity. At present, numerous
Externí odkaz:
https://doaj.org/article/c1f69a823e67430ca95ffab72cb47f36
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 20, Iss 4, Pp 245-256 (2020)
One of priority issues of the present-day healthcare system is development of new vaccines and improvement of existing ones due to decreasing immunocompetence of the population, emergence of new infections and reemergence of old ones which were previ
Externí odkaz:
https://doaj.org/article/3e75ca38bcc84ab2a217503a475ee867
Autor:
A. A. Soldatov, Zh. I. Avdeeva, V. P. Bondarev, V. A. Merkulov, V. D. Mosyagin, V. B. Ivanov, D. V. Gorenkov, L. M. Khantimirova
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 20, Iss 4, Pp 228-244 (2020)
The progress of the COVID-19 pandemic initiated research to develop vaccines against this novel coronavirus infection. The WHO and national regulatory authorities in many countries have elaborated guidelines to speed up the development and authorisat
Externí odkaz:
https://doaj.org/article/5704503e84ec4e75b3394f7e777a9f1b
Autor:
N. N. Besednova, I. D. Makarenkova, L. N. Fedyanina, ZH. I. Avdeeva, S. P. Kryzshanovsky, T. A. Kuznetsova, T. S. Zaporozhets
Publikováno v:
Антибиотики и Химиотерапия, Vol 63, Iss 5-6, Pp 52-67 (2020)
The review article presents the materials of recent years dedicated to the analysis of modern data about the possible aspects of the use of deoxyribonucleic acid (DNA) and oligodesoxinucleotides (natural and synthetic) from pro - and eukaryotes for t
Externí odkaz:
https://doaj.org/article/43b0a08094ef4f038db288683a97fe25